Inari Medical (Inari Medical) ROCE % : -2.30% (As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Inari Medical ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Inari Medical's annualized ROCE % for the quarter that ended in Dec. 2023 was -2.30%.

Inari Medical ROCE % Historical Data

The historical data trend for Inari Medical's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Inari Medical ROCE % Chart

Inari Medical Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

-0.90

12.65

4.68

-7.22

0.85

Inari Medical Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
ROCE %	Get a 7-Day Free Trial															-4.24	-1.02	2.65	4.75	-2.30

Inari Medical ROCE % Calculation

Inari Medical's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	4.442	/	( ( (504.152 - 56.174)	+	(674.235 - 76.339) )	/ 2 )
	=	4.442	/	( (447.978	+	597.896)	/ 2 )
	=	4.442	/	522.937
	=	0.85 %

Inari Medical's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	-12.42	/	( ( (548.835 - 66.066)	+	(674.235 - 76.339) )	/ 2 )
	=	-12.42	/	( ( 482.769	+	597.896 )	/ 2 )
	=	-12.42	/	540.3325
	=	-2.30 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

Inari Medical (NAS:NARI) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Inari Medical ROCE % Related Terms

Thank you for viewing the detailed overview of Inari Medical's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Inari Medical (Inari Medical) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Inari Medical Inc (NAS:NARI) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

IM7:Germany

Address

6001 Oak Canyon, Suite 100, Irvine, CA, USA, 92618

Website

https://www.inarimedical.com

Inari Medical Inc is a medical device company focused on developing products to treat patients suffering from Chronic Venous Disease. Its product portfolio includes ClotTriever, for the removal of the clot from peripheral blood vessels and treats patients suffering from deep vein thrombosis. The FlowTriever System product is used for the treatment of pulmonary embolism. The company generates revenue from the sale of ClotTriever and FlowTriever systems directly to hospitals located in the United States. Majority of revenue is generated from FlowTriever system.

Executives

William Hoffman	director, officer: President and CEO	C/O INARI MEDICAL, INC., 9 PARKER, SUITE 100, IRVINE CA 92618
Mitch C. Hill,	officer: Chief Financial Officer	1009 TENNYSON DRIVE, SOUTHLAKE TX 76902
Andrew Hykes	officer: Chief Operating Officer	C/O INARI MEDICAL, INC., 9 PARKER AVENUE, SUITE 100, IRVINE CA 92618
Thomas Tu	officer: Chief Medical Officer	C/O INARI MEDICAL, INC., 9 PARKER AVENUE, SUITE 100, IRVINE CA 92618
Donald B Milder	director	ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Robert Keith Warner	director	C/O RXSIGHT, INC., 100 COLUMBIA, ALISO VIEJO CA 92656
Catherine M. Szyman	director	C/O EDWARDS LIFESCIENCES CORPORATION, ONE EDWARDS WAY, IRVINE CA 92614
Cynthia L Lucchese	director	7966 N. ILLINOIS STREET, INDIANAPOLIS IN 46260
Mead Dana G Jr.	director	2750 SAND HILL ROAD, MENLO PARK CA 94025
Rebecca Chambers	director	3052 ORCHARD DR., SAN JOSE CA 95134
Jonathan D Root	director	2735 SAND HILL ROAD, MENLO PARK CA 94025
Cooperatieve Gilde Healthcare Iv U.a.	10 percent owner	NEWTONLANN 51, UTRECHT P7 3508AB
Kirk G. Nielsen	director, 10 percent owner	ONE SANSOME STREET, SUITE 3630, SAN FRANCISCO CA 94104
Gilde Healthcare Iv Management B.v.	10 percent owner	NEWTONLAAN 91, UTRECHT P7 3584 BP
Gilde Healthcare Holding B.v.	10 percent owner	NEWTONLAAN 91, PO BOX 85067, 3508 UTRECHT P7 AB